BOSTON—Jing “Andy” Chen, Ph.D., has joined Womble Bond Dickinson’s Boston-based Life Science and Pharmaceutical Team as a patent agent (limited recognition).
Dr. Chen brings a background in molecular and cellular biology, microbiology, CRISPR, and label-free imaging techniques to his patent practice, having earned a Ph.D. in Molecular Biology from Purdue University. His work includes conducting research into malaria parasite imaging and disease mechanisms. His research has been cited in numerous academic publications, both in the U.S. and China. Dr. Chen is fluent in Mandarin. Dr. Chen’s experience in patent prosecution includes a range of technologies, including biologics, RNAi, gene therapy and vaccines.
At Womble Bond Dickinson, Dr. Chen joins a seasoned life science patent team who opened the firm’s Boston office in 2017. Dr. Chen’s addition brings the growing Boston life science patent practice to 14 attorneys, patent agents and science advisors. Womble Bond Dickinson provides a full range of services to the life sciences sector, including IP litigation, patent procurement and investigations, IP transactions, trademarks/copyright, FDA regulatory guidance product liability litigation, and government contracts.
He joins Womble Bond Dickinson from Lathrop GPM.